Free drug-development software gains traction across pharma and regulators
A year after launching an open-source platform for modeling how drugs work in the body, developers say the tool is now used by over 100 institutions—including major pharmaceutical companies and regulatory agencies. The shift toward shared, transparent software could accelerate drug approvals and cut development costs by letting firms collaborate on complex calculations that traditionally required expensive proprietary tools.
Originaltitel: Open Systems Pharmacology Community Conference ( <scp>OSP</scp> ‐ <scp>CC</scp> ) Proceedings 2025
Developed at Bayer Technology Services, PK-Sim and MoBi transitioned into the Open Systems Pharmacology (OSP) Suite, released as free open-source software in 2017. An active community with stakeholders from academia, industries, and regulators contributes to the continuous improvement of open-source model-informed drug development (MIDD). This perspective summarizes the latest advancements presented at the second OSP Community Conference (OSP-CC) hosted from 29 to 30th of September 2025 at Sanofi Paris, that gathered over 100 attendees from more than 40 institutions.